PBAC's latest decision on Fluticasone furoate: Recommended with restriction (2019). Considered for Maintenance treatment of asthma in children aged 5 to 11 years.
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2015
Submissions
3
2015 → 2019
Eligible population
Children aged 5 to 11 years with inadequately controlled asthma.
Therapy area
Respiratory
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Change in morning peak expiratory flow (PEF)
Pivotal trial size
573 patients
Key trials
HZA106855
Comparator
fluticasone propionate (FP) 100 mcg twice daily
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated.
Submission history
Nov 2015: Recommended · Unrestricted
Mar 2017: Noted · Unrestricted
Jul 2019: Recommended with restriction · Unrestricted